SIGHT.PA Stock - GenSight Biologics S.A.
Unlock GoAI Insights for SIGHT.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.63M | $1.27M | $2.58M | $5.28M | $4.39M |
| Gross Profit | $2.63M | $3.00M | $2.58M | $5.28M | $4.39M |
| Gross Margin | 100.0% | 236.8% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-15,813,000 | $-29,696,000 | $-27,835,000 | $-28,126,000 | $-24,934,000 |
| Net Income | $-14,001,000 | $-26,220,000 | $-27,624,000 | $-28,617,000 | $-34,016,000 |
| Net Margin | -533.4% | -2069.5% | -1069.9% | -542.4% | -774.1% |
| EPS | $-0.15 | $-0.54 | $-0.60 | $-0.63 | $-0.97 |
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
SIGHT.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 21, 2026 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | $-0.07 | — | — |
Q4 2024 | Oct 24, 2024 | — | $-0.07 | — | — |
Q2 2024 | Jun 20, 2024 | — | $-0.28 | — | — |
Q4 2023 | Oct 26, 2023 | — | $-0.26 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.36 | — | — |
Q4 2022 | Oct 28, 2022 | — | $-0.23 | — | — |
Q2 2022 | Apr 21, 2022 | — | $-0.44 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-0.19 | — | — |
Q1 2021 | Mar 10, 2021 | — | $-0.54 | — | — |
Q3 2020 | Jul 30, 2020 | — | $-0.43 | — | — |
Q1 2020 | Mar 12, 2020 | — | $-0.45 | — | — |
Q3 2019 | Jul 24, 2019 | — | $-0.63 | — | — |
Q2 2019 | Apr 24, 2019 | — | $-0.89 | — | — |
Q4 2018 | Oct 24, 2018 | — | $-0.48 | — | — |
Q1 2018 | Feb 28, 2018 | — | $-0.58 | — | — |
Q4 2017 | Oct 26, 2017 | — | $-0.51 | — | — |
Q1 2017 | Mar 13, 2017 | — | $-0.68 | — | — |
Q4 2016 | Oct 13, 2016 | — | $-0.68 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.67 | — | — |
Latest News
Frequently Asked Questions about SIGHT.PA
What is SIGHT.PA's current stock price?
What is the analyst price target for SIGHT.PA?
What sector is GenSight Biologics S.A. in?
What is SIGHT.PA's market cap?
Does SIGHT.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SIGHT.PA for comparison